Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab with Chemotherapy ± PD-1/PD-L1 Inhibitor in HER2+ Biliary Tract Cancer
NCT06818773Phase 4Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of inetetamab in biliary tract cancer (BTC), sponsored by Eastern Hepatobiliary Surgery Hospital. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06818773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818773.